Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 9Phase 3 6Phase 1/2 3

Status

Completed 4Active not recruiting 2

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 4Genitourinary 2Tumor-Agnostic 1

Conditions

Fallopian Tube Neoplasms 4Ovarian Neoplasms 3Carcinoma, Ovarian Epithelial 3Neoplasms 2Recurrence 1Prostatic Neoplasms 1Pathologic Complete Response 1Metastatic Castration Resistant Prostate Cancer 1Genital Neoplasms, Male 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × rucaparib × Clear all
NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT02975934 2025-07-25

TRITON3

pharmaand GmbH

Phase 3 Completed
405 enrolled 34 charts 1 FDA
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03522246 2025-06-24

ATHENA

pharmaand GmbH

Phase 3 Active not recruiting
1,097 enrolled 26 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT04676334 2024-05-07

CATCH-R

pharmaand GmbH

Phase 3 Completed
34 enrolled 9 charts
GenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Male, Ovarian Neoplasms, Prostatic Neoplasms

NCT01968213 2023-06-09

ARIEL3

pharmaand GmbH

Phase 3 Completed
564 enrolled 18 charts 1 FDA
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

pharmaand GmbH

Phase 3 Completed
349 enrolled 29 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡